184 related articles for article (PubMed ID: 19675719)
21. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
22. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
23. Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen.
Schreiber WE; Endres DB; McDowell GA; Palomaki GE; Elin RJ; Klee GG; Wang E
Arch Pathol Lab Med; 2005 Mar; 129(3):331-7. PubMed ID: 15737027
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.
Basu A; Seth S; Chauhan AK; Bansal N; Arora K; Mahaur A
Ann Transl Med; 2016 Feb; 4(4):71. PubMed ID: 27004218
[TBL] [Abstract][Full Text] [Related]
25. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma.
Lopez JB; Balasegaram M; Timor J; Thambyrajah V
Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242
[TBL] [Abstract][Full Text] [Related]
26. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.
Molina R; Bonfrer J; Banfi G; Bugugnani MJ; Cornu F; Hannemann-Pohl K; Hubl W; Merz O; Bach M; Mack M
Clin Lab; 2000; 46(3-4):169-79. PubMed ID: 10791126
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
Shan D; Cheng S; Ma Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
[TBL] [Abstract][Full Text] [Related]
28. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Colli A; Nadarevic T; Miletic D; Giljaca V; Fraquelli M; Štimac D; Casazza G
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013346. PubMed ID: 33855699
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of plasma tumor markers in germinal tumors of the testis].
Blacker C; Feinstein MC; Roger M; Zimmer R; Scholler R
Ann Med Interne (Paris); 1984; 135(5):376-80. PubMed ID: 6207755
[TBL] [Abstract][Full Text] [Related]
30. 'Oncocheck': an international external quality assessment scheme for immunoassays of tumor markers.
Cohen R; Zucchelli GC; Fraysse M; Pilo A; Rigault MY; Grillet S; Bizollon CA
Nucl Med Biol; 1994 Apr; 21(3):483-93. PubMed ID: 9234309
[TBL] [Abstract][Full Text] [Related]
31. [Clinical relevance of tumor markers].
Lamerz R
Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
[TBL] [Abstract][Full Text] [Related]
32. Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.
Desai S; Guddati AK
World J Oncol; 2023 Feb; 14(1):4-14. PubMed ID: 36895994
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of abnormal levels of serum tumour markers in elderly people.
Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M
Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528
[TBL] [Abstract][Full Text] [Related]
34. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
35. First trimester serum tests for Down's syndrome screening.
Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011975. PubMed ID: 26617074
[TBL] [Abstract][Full Text] [Related]
36. [Application of multiple tumor markers's protein chip in the screen program of the elderly].
Yan HY; Zhong RH; Li J; Luo XH; Chen R
Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Sep; 32(9):924-6. PubMed ID: 22340884
[TBL] [Abstract][Full Text] [Related]
37. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
38. [Tumor markers in C-cell cancer].
Raue F; Schmidt-Gayk H; Ziegler R
Dtsch Med Wochenschr; 1983 Feb; 108(8):283-7. PubMed ID: 6297868
[TBL] [Abstract][Full Text] [Related]
39. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
40. Blood biomarkers for the non-invasive diagnosis of endometriosis.
Nisenblat V; Bossuyt PM; Shaikh R; Farquhar C; Jordan V; Scheffers CS; Mol BW; Johnson N; Hull ML
Cochrane Database Syst Rev; 2016 May; 2016(5):CD012179. PubMed ID: 27132058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
